| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825719 | Clinical Therapeutics | 2013 | 9 Pages |
Abstract
The FDC capsule was bioequivalent to the concurrent administration of lamivudine + adefovir dipivoxil tablets based on the 90% CIs of the GMRs for Cmax, AUC0-â, AUC0-last, and t12 (all were between 0.80 and 1.25). Both treatments were well-tolerated. Clinicaltrial.gov identifier: NCT01353742.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Benny S.P. PhD, Stephen MSPH, Steve PharmD, Shuguang PhD, Tanya T.W. PhD, Jones C.M. MBChB, Brian MD,